January 23rd 2024
The Boxed Warning reflects FDA research into severe adverse events including hospitalization and death in persons with CKD treated with denosumab.
September 11th 2023
ASCO Breast: Aches and Pains Prompt Some Women to Stop Aromatase Inhibitors
September 11th 2007SAN FRANCISCO -- Joint or muscle pain or both prompted 13% of breast cancer patients enrolled in a trial comparing exemestane (Aromasin) with letrozole (Femara) to discontinue treatment, researchers reported here.
Prediction Tool Targets Undifferentiated-arthritis Dilemma: To Treat or Not to Treat?
May 31st 2007A prediction model and simple scoring form developed by Dutch rheumatologists can help physicians determine which early-arthritis patients are most likely to develop rheumatoid arthritis and should therefore receive prompt, aggressive treatment.
FDA Advisers Give Overwhelming Rejection to Etoricoxib (Arcoxia)
April 12th 2007GAITHERSBURG, Md. -- By a vote 20 to one, FDA advisers recommended today against approval of Merck's Cox-2 inhibitor etoricoxib (Arcoxia), declaring that the cardiovascular risks of the drug outweigh its benefits for easing arthritis pain.
Upper Extremity Swelling in a Smoker
April 1st 2007A 57-year-old woman presents with swelling of the hands that began several weeks earlier and is now worsening. She denies joint pain, and she has no history of trauma or significant vascular disease. She has had pneumonia several times; each episode was successfully treated with antibiotics. She has smoked 2 packs of cigarettes a day for the past 20 years
Diffuse alveolar hemorrhage in a patient with SLE
March 1st 2007The authors present a case in which the initial manifestation of systemic lupus erythematosus (SLE) was diffuse alveolar hemorrhage (DAH), which is a rare presentation that carries a high risk of death. The patient failed to respond to standard therapy but was successfully treated with plasmapheresis.